The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial
Abstract
BACKGROUND The optimal technique of percutaneous coronary intervention in patients at high bleeding risk is not known. The hypothesis of the DEBUT trial was that percutaneous coronary intervention with drug-coated balloons is non-inferior to percutaneous coronary intervention with bare-metal stents for this population. METHODS The DEBUT trial is a randomised, single-blind non-inferiority trial done at five sites in Finland. Patients were eligible if they had an ischaemic de-novo lesion in a coronary artery or bypass graft that could be treated with drug-coated balloons, at least one risk factor for bleeding, and a reference vessel diameter of 2·5-4·0 mm. Those with myocardial infarction with ST-elevation, bifurcation lesions needing a two-stent technique, in-stent restenosis, and flow-limiting dissection or substantial recoil (>30%) of the target lesion after predilation were excluded. After successful predilation of the target lesion, patients were randomly assigned (1:1), by use of a computer-generated random sequence, to percutaneous coronary intervention with a balloon coated with paclitaxel and iopromide or a bare-metal stent. The primary outcome was major adverse cardiac events at 9 months. Non-inferiority was shown if the absolute risk difference was no more than 3%. All prespecified analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01781546. FINDINGS Between May 22, 2013, and Jan 16, 2017, 220 patients were recruited for the study and 208 patients were assigned to percutaneous coronary intervention with drug-coated balloon (n=102) or bare metal stent (n=106). At 9 months, major adverse cardiac events had occurred in one patient (1%) in the drug-coated balloon group and in 15 patients (14%) in the bare-metal stent group (absolute risk difference -13·2 percentage points [95% CI -6·2 to -21·1], risk ratio 0·07 [95% CI 0·01 to 0·52]; p<0·00001 for non-inferiority and p=0·00034 for superiority). Two definitive stent thrombosis events occurred in the bare metal stent group but no acute vessel closures in the drug-coated balloon group. INTERPRETATIONS Percutaneous coronary intervention with drug-coated balloon was superior to bare-metal stents in patients at bleeding risk. The drug-coated balloon-only coronary intervention is a novel strategy to treat this difficult patient population. Comparison of this approach to the new generation drug-eluting stents is warranted in the future. FUNDING B Braun Medical AG, AstraZeneca, and Competitive State Research Funding of the Kuopio University Hospital Catchment Area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
Prevention of bleeding in patients with atrial fibrillation undergoing PCI
Gibson, C. M., Mehran, R., Bode, C., Halperin, J., Verheugt, F. W., Wildgoose, P., Birmingham, M., Ianus, J., Burton, P., van Eickels, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611594 · Cited by 1,590
Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation
Cannon, C. P., Bhatt, D. L., Oldgren, J., Lip, G. Y. H., Ellis, S. G., Kimura, T., Maeng, M., Merkely, B., Zeymer, U., Gropper, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708454 · Cited by 1,383
Fihn, S. D., Blankenship, J. C., Alexander, K. P., Bittl, J. A., Byrne, J. G., Fletcher, B. J., Fonarow, G. C., Lange, R. A., Levine, G. N., Maddox, T. M., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000095 · Cited by 1,029
Cited by
Drug-Coated Balloons for Coronary Artery Disease
Jeger, R. V., Eccleshall, S., Wan Ahmad, W. A., Ge, J., Poerner, T. C., Shin, E.-S., Alfonso, F., Latib, A., Ong, P. J., Rissanen, T. T., et al. (2020) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.02.043 · Cited by 600
Self-citationJeger, R. V., Farah, A., Ohlow, M.-A., Mangner, N., Möbius-Winkler, S., Weilenmann, D., Wöhrle, J., Stachel, G., Markovic, S., Leibundgut, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32173-5 · Cited by 279
Metadata
- Authors
- Rissanen, T. T., Uskela, S., Eränen, J., Mäntylä, P., Olli, A., Romppanen, H., Siljander, A., Pietilä, M., Minkkinen, M. J., Tervo, J., Kärkkäinen, J. M., Vatanen, A., Perälä, A., Müller, M., Porela, P., & Palojoki, E.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 394
- Issue
- 10194
- Pages
- 230-239
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2951346441
- Cited by
- 252
- References
- 4
- FWCI
- 17.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)31126-2
- The paper
- Rissanen, T. T., Uskela, S., Eränen, J., Mäntylä, P., Olli, A., Romppanen, H., Siljander, A., Pietilä, M., Minkkinen, M. J., Tervo, J., Kärkkäinen, J. M., Vatanen, A., Perälä, A., Müller, M., Porela, P., & Palojoki, E. (2019). Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)31126-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.